Evidence map›Paper›PMID 12121919›Full record

ArticleAntimicrobial agents and chemotherapy2002

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.

Nir Osherov, Gregory S May, Nathaniel D Albert, D P Kontoyiannis

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00388167 (PROCAS), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00388167 completednot on this mapstarted 2004, after this paper: background citation

PROCAS: Study Observational Prospective and Multicenter to Determine the Clinic Effectiveness and the Safety of Caspofungin Acetate (CANCIDAS®) in the Treatment of Invader Fungal Infection

TypeobservationalSponsorPETHEMA FoundationRan2004 to 2008Enrolled320ConditionsCandidiasis, AspergillosisArmsCaspofungin
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Resistance to echinocandin-class antifungal drugs.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2007
    Review
  9. Comparison of echinocandin antifungals.Therapeutics and clinical risk management · 2007
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Nir OsherovDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Gregory S May
Nathaniel D Albert
D P Kontoyiannis
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS CA 16672NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Caspofungin inhibits the synthesis of 1, 3-beta-D-glucan, an essential cell wall target in fungi. Genetic studies in the model yeast Saccharomyces cerevisiae have shown that mutations in FKS1 and FKS2 genes result in caspofungin resistance. However, direct demonstration of the role of gene overexpression in caspofungin resistance has been lacking. We transformed wild-type S. cerevisiae with an S. cerevisiae URA3-based GAL1 cDNA library and selected transformants in glucose synthetic complete plates lacking uracil (glucose SC minus uracil plates). We then moved the transformants to galactose SC minus uracil plates containing caspofungin (1 microg/ml) and looked for caspofungin-resistant colonies. We retested the candidates (true positives were sensitive on glucose caspofungin and resistant on galactose caspofungin media, respectively). We identified 16 caspofungin-resistant candidates. Restriction analysis and hybridization confirmed that 15 of the 16 clones were identical. We sequenced one of the cDNA clones and found that it contained the cDNA for SBE2. SBE2 has been described in S. cerevisiae to encode a Golgi protein involved in the transport of cell wall components (B. Santos and M. Snyder, Mol. Biol. Cell, 11:435-452, 2000). The SBE2 cDNA plasmid conferred again galactose-dependent caspofungin resistance when transformed back into the wild-type S. cerevisiae. Finally, the SBE2 deletion mutant was hypersensitive to caspofungin. In conclusion, overexpression of Sbe2p under the regulated control of the GAL1 promoter results in caspofungin resistance in S. cerevisiae. This transport pathway may provide insight into the tolerance or lack of sensitivity to caspofungin of some pathogenic fungi.

Indexed as

PeptidesPeptides, CyclicSaccharomyces cerevisiae ProteinsAnti-Bacterial AgentsAntifungal AgentsCaspofunginCell WallDNA, FungalDrug Resistance, MicrobialEchinocandinsFungal ProteinsGalactoseGlucoseGolgi ApparatusLipopeptidesMembrane GlycoproteinsAnti-Bacterial AgentsAntifungal AgentsCaspofunginDNA, FungalEchinocandinsFungal ProteinsGalactoseGlucoseLipopeptidesMembrane GlycoproteinsPeptidesPeptides, CyclicSaccharomyces cerevisiae ProteinsSBE2 protein, S cerevisiaeVesicular Transport Proteins

Identifiers

PMID12121919
PMCPMC127366
OpenAlexW2138652877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.